Table 1.
Demographics, baseline characteristics and treatment of the studied cohort.
| Parameters (n = 90) | Mean ± SD |
|---|---|
| Age (years) | 42.5 ± 14.9 |
| Gender (M/F) | 38/52 |
| BMI (kg/m2) | 30.1 ± 7.8 |
| *ESS baseline | 18.9 ± 3.4 |
| *ESS final | 14.5 ± 5.1 |
| *Cataplexy events/week baseline | 26.2 ± 22.7 |
| *Cataplexy events/week final | 4.4 ± 10.8 |
| Patients on stimulants or wake promoters, n (%) | 36 (40) |
| Patients on anticataplectic agents, n (%) | 7 (7.8) |
| Patients on combination treatment, n (%) | 44 (48.9) |
| Patients on no treatment, n (%) | 3 (3.3) |
| FU time (months) | 35.5 (IQR 11.0–54.0) |
BMI, Body Mass Index; ESS, Epworth Sleepiness Scale score. *: Baseline and final term uses as reference points the status before sodium oxybate initiation and after optimum dose of sodium oxybate had been achieved, respectively. FU, follow-up is reported as median; IQR, interquartile range. The term combination treatment refers to stimulants or wake promoters and anti-cataplectic agents.